Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study

This study used samples from the Blood & Marrow Transplant Clinical Trials Network (BMT CTN) to identify new biomarker models to predict acute GVHD (aGVHD) and overall mortality. They added two new biomarkers, Galactin-3 (Gal-3) and lymphocyte activation gene 3 (LAG-3), to the previously identified biomarkers. Increased Gal-3 levels at day +7 predicted the development of aGVHD grades II-IV, while higher day +14 levels predicted overall mortality in patients who received reduced intensity conditioning. Elevated LAG-3 levels at day +21 were associated with less severe aGVHD. Researchers also confirmed that the previously studied biomarkers Reg3A, ST2, TIM-3, and TNFR1 predict severe aGVHD at day +14 and day +21.